[Gefitinib as targeted treatment for non-small-cell lung cancer].
Knuuttila
Aija
A
HYKS:n keuhkosairauksien klinikka, HUS. aija.knuuttila@hus.fi
Karjalainen
Eeva-Maija
EM
Rouhos
Annamari
A
Mali
Pekka
P
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016503:Drug Delivery Systems; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D005387:Finland; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011788:Quality of Life; D011799:Quinazolines / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D016896:Treatment Outcome
D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib